Skip to main content
TipRanks
Go Ultimate75% OFF

Syngene International Ltd. (SYNGENE) AI Stock Analysis

7 Followers
IN:SYNGENE

Syngene International Ltd.

(NSE:SYNGENE)

Select Model
Rating:67Neutral
Price Target:INR 490.00â–²(8.44% Upside)
Action:reiterated
Date:10/29/26

The score is supported primarily by a strong balance sheet and historical revenue growth, with additional support from generally constructive technical indicators. Recent profitability and cash-flow concerns, combined with a high P/E and low dividend yield, materially constrain the overall score.

Positive Factors
Conservative balance sheetLow and improving leverage, together with a growing equity base, gives Syngene financial resilience and flexibility. This supports continued investment in research, development and manufacturing capacity while reducing the balance-sheet burden during periods of weaker earnings.
Negative Factors
FY2026 revenue contractionThe sharp latest-year revenue decline interrupts Syngene’s prior growth trajectory and signals weaker demand or project activity in the near term. Sustained contraction would reduce operating leverage and make it harder to support investment while preserving historical margins.

Syngene International Ltd. (SYNGENE) vs. iShares MSCI India ETF (INDA)

-50%-40%-30%-20%-10%0%10%IN:SYNGENE-29.46%INDA-2.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 148.36B
Dividend Yield
0.28%
Average Volume (3M)
147.69K
Price to Earnings (P/E)
97.6
Beta (1Y)
0.90
Revenue Growth
-5.99%
EPS Growth
-60.30%
Country
India
Employees
6,692
Sector
Healthcare
Sector Strength
51
Industry
Specialty Business Services

Syngene International Ltd. Business Overview & Revenue Model

Company Description

Syngene International Limited, an India-based contract research and manufacturing organization (CRAMO), offers a wide array of drug discovery and development solutions to clients across India, the United States, and other international markets. The c...

Syngene International Ltd. Financial Statement Overview

Summary

Strong balance-sheet quality and long-term revenue growth support the score, but FY2026 margin compression, lower return on equity, and volatile free cash flow reduce financial strength.

Income Statement

72Positive

Balance Sheet

88Very Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue35.22B37.39B36.42B34.89B31.93B26.04B
Gross Profit11.39B12.62B24.41B23.50B21.56B17.12B
EBITDA8.23B9.13B10.47B10.73B9.84B7.43B
Net Income1.86B3.17B4.96B5.10B4.64B3.96B
Balance Sheet
Total Assets66.58B70.55B67.96B61.52B58.31B55.64B
Cash, Cash Equivalents and Short-Term Investments5.30B12.89B13.97B10.77B13.54B12.81B
Total Debt5.07B4.58B5.78B5.55B8.15B10.22B
Total Liabilities18.00B22.16B20.69B18.94B22.13B22.66B
Stockholders Equity48.59B48.39B47.27B42.58B36.18B32.98B
Cash Flow
Free Cash Flow06.11B3.98B5.50B3.05B1.05B
Operating Cash Flow09.55B11.68B10.42B8.38B5.81B
Investing Cash Flow0-9.11B-7.45B-4.96B-6.88B-6.12B
Financing Cash Flow0-2.04B-1.42B-5.51B-3.40B-313.00M

Syngene International Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price451.85

Price Trends

50DMA391.97Positive
100DMA400.81Positive
200DMA418.35Positive

Market Momentum

MACD16.24Negative
RSI68.01Neutral
STOCH70.40Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SYNGENE, the sentiment is Positive. The current price of 451.85 is above the 20-day moving average (MA) of 417.24, above the 50-day MA of 391.97, and above the 200-day MA of 418.35, indicating a bullish trend. The MACD of 16.24 indicates Negative momentum. The RSI at 68.01 is Neutral, neither overbought nor oversold. The STOCH value of 70.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SYNGENE.

Syngene International Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IN:SYNGENE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:ANTHEMIN:ANTHEM73OutperformINR 528.58B87.17―0.21%-1.20%18.53%
IN:SYNGENEIN:SYNGENE67NeutralINR 176.65B97.56―0.28%-5.99%-60.30%
IN:CONCORDBIOIN:CONCORDBIO57NeutralINR 116.38B40.65―1.38%4.02%-12.81%
IN:DCALIN:DCAL55NeutralINR 18.59B26.57――-0.11%-184.93%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IN:BIOCONIN:BIOCON47NeutralINR 589.95B121.87―0.14%5.70%-24.72%
IN:PANACEABIOIN:PANACEABIO47NeutralINR 21.64B111.61――19.43%―

* Healthcare Sector Average

Performance Comparison

-50%0%50%IN:SYNGENEIN:BIOCONIN:CONCORDBIOIN:DCALIN:PANACEABIOIN:ANTHEMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:SYNGENE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:SYNGENESyngene International Ltd.451.85-186.19-29.18%
IN:BIOCONBiocon Limited366.00-28.18-7.15%
IN:CONCORDBIOConcord Biotech Ltd.548.40-152.83-21.79%
IN:DCALDishman Carbogen Amcis Ltd.115.85-116.25-50.09%
IN:PANACEABIOPanacea Biotec Limited336.25-12.30-3.53%
IN:ANTHEMAnthem Biosciences Limited950.95320.8450.92%

Syngene International Ltd. Corporate Events

Syngene posts Q2 FY27 earnings call audio for investors

Oct 28, 2026

Syngene International Limited has notified the Indian stock exchanges that the audio recording of its Q2 FY27 post-earnings call held on October 28, 2026 has been uploaded to the company’s website. The disclosure has been made under Regulation 30 of...

Syngene Publishes Investor Presentation for September 2026 Period

Oct 27, 2026

Syngene International Ltd. has released an investor presentation for the quarter and half year ended September 30, 2026, in line with Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements Regulations, 2015. The document, intended fo...

Syngene Announces Resignation of Corporate Affairs Head

Sep 21, 2026

Syngene International Ltd. has announced the resignation of Mr. Pramuch Goel, Head of Corporate Affairs & Communications and a member of the Executive Committee, effective at the close of business on September 21, 2026. The company has notified the B...

Syngene Schedules Analyst Meet at Kotak Healthcare Forum 2026

Sep 12, 2026

Syngene International Ltd. has scheduled a meeting with analysts and institutional investors at the Healthcare Forum 2026 organized by Kotak in Mumbai on September 17, 2026. The engagement will take place as a physical group and one-on-one investor c...

Syngene Grants 1.43 Million Performance Share Units Under 2023 Long-Term Incentive Plan

Sep 1, 2026

Syngene International has granted 1,426,061 Performance Share Units (PSUs) to eligible employees under its Long Term Incentive Performance Share Plan 2023, following approval by the company’s Nomination and Remuneration Committee. The grant, aligned...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026